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Background: Aromatase deficiency is a rare, autosomal recessive disorder of which there are approximately twenty
four case reports. The aromatase enzyme is crucial in the biosynthesis of oestrogens from androgens. The
phenotype of aromatase deficiency therefore is the result of androgen excess and oestrogen deficiency in the
absence of normal aromatase activity. We report the first case of aromatase deficiency diagnosed in a female adult,
at the age of 32 years, due to a novel duplication in the aromatase gene.
Case presentation: A 32 year old Indian woman presented with a history of gender assignment difficulties at birth, lack
of pubertal development, osteopaenia with fracture and tall stature. She had central obesity, impaired fasting glucose and
borderline hypertension. Past examinations had revealed partial fusion of urethra and vagina, hypoplastic uterus and streak
ovaries. The ovaries had been excised due to malignant risk after an initial clinical diagnosis of Turner’s syndrome with Y
mosaicism. Oestrogen replacement commenced shortly after her fracture, in adulthood. After reassessment, aromatase
deficiency was diagnosed. Sequencing of the coding exons of the aromatase (CYP19A1; OMIM 109710) gene revealed a
novel 27-base duplication in exon 8 (p.Ala306_Ser314dup). This duplication, occurring within the aromatase α-helix, would
be likely to disrupt substrate (androgen) and cofactor (protoporphyrin IX) binding, resulting in a lack of oestrogen synthesis.
Conclusions: We report a female with a phenotype compatible with aromatase deficiency which was unrecognised
until adulthood and found she had a novel duplication in CYP19A1. Previous case reports have described polycystic
ovarian morphology, especially in childhood and adolescence, but never streak ovaries. This may reflect the few
adult cases reported, that aromatase deficiency in females is generally diagnosed at birth and oestrogen treatment
commences decades earlier than occurred in our patient. Streak ovaries are consistent with the phenotype of the
aromatase knockout mouse followed through adulthood. The observed clinical features of obesity, dysglycaemia
and hypertension, are compatible with the observation that lack of a counterbalancing effect of oestrogen on tissue
androgens until adulthood may lead to a metabolic syndrome phenotype. This report broadens the spectra of
phenotype and genetic mutations underlying this rare disorder.
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Human aromatase is a 58KDa protein which was first iso-
lated from the placenta in the 1980s [1]. Tissues expressing
aromatase include the granulosa cells and lutea corpora of
the ovary, Leydig and Sertoli cells of the testis, breast, syn-
cytiotrophoblast of the placenta, neurons, brain (including
hypothalamus), liver, pre-adipocytes and fibroblasts, vascu-
lar smooth muscle cells, chondrocytes and osteoblasts [2].* Correspondence: lucia.gagliardi@health.sa.gov.au
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reproduction in any medium, provided the orAromatase is a cytochrome P450 critical in the biosynthesis
of oestrogen since it converts androgenic substrates, pri-
marily testosterone and androstenedione, to oestradiol and
oestrone, respectively [2]. In pregnancy, placental aroma-
tisation of 16-hydroxy-dehydroepiandrosterone sulphate,
arising from foetal liver hydroxylation of dehydroepiandros-
terone sulphate produced by the foetal adrenal, is the major
source of circulating oestrogens; the activity of placental
aromatase protects the foetus against the virilising action of
foetal androgens [3]. Placental aromatisation of foetal an-
drogens also prevents high levels from reaching the mater-
nal circulation, where they would result in maternal
virilisation during pregnancy, subsiding post-partum.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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OMIM 109710) is a 120Kb gene on chromosome 15q21.1,
comprising nine coding exons (2-10) spanning approxi-
mately 35Kb; there are multiple first exons that are involved
in tissue-specific expression [4-6]. These exons generate al-
ternative splicing such that the coding region, and hence
protein sequence, is conserved in every tissue. Within the
aromatase protein, the most highly conserved region (the
core region), consists of a four-helix bundle, two β sheets
and the haem-binding region [7].
Aromatase deficiency is an autosomal recessive disorder
due to mutations of the CYP19A1 gene which result in re-
duced aromatase activity. There have been approximately
twenty four cases of aromatase deficiency reported, includ-
ing the original case reported by Shozu and colleagues in
1991 [8-12].
Clinical features of CYP19A1 deficiency include maternal
virilization during pregnancy due to non-aromatization of
foetal-derived androgens which resolves gradually postpar-
tum, foetal virilisation of external genitalia and symptoms of
haemorrhagic ovarian cysts in childhood [13-18]. Adre-
narche is reportedly normal; however there is primary
amenorrhoea and lack of breast development [15]. Elevated
gonadotropins and hyperandrogenism are often present
[16]. Virilization may progress with age – factors determin-
ing the presence and rate of progression are not established
[15,19]. Delayed epiphyseal fusion and decreased bone dens-
ity are reported [15,16]. Variation in phenotypic expression
including some breast and uterine development may be due
to partial aromatase activity. The natural history of
CYP19A1 deficiency in females is largely unknown because
early diagnosis leads to timely treatment. Males are usually
diagnosed later in life, are tall due to delayed epiphysealFigure 1 Clinical photographs taken at the patient’s laparoscopy. The hyclosure and have osteoporosis due to impaired bone min-
eralisation; these clinical features are comparable to those
seen in patients with oestrogen receptor mutations; altered
testis size and spermatogenesis may also be due to aroma-
tase deficiency [15,20]. A metabolic syndrome-like picture of
abdominal obesity, hepatic steatosis and insulin resistance
has been well described in males; in females metabolic syn-
drome has been noted to be more prominent in cases where
oestrogen treatment was delayed until adulthood [12,21-24].
Here, we report for the first time a female patient diag-
nosed with aromatase deficiency during adulthood. We
found this patient to have a novel mutation in exon 8 of
CYP19A1, which broadens the spectrum of mutations
underlying aromatase deficiency.Case presentation
The patient was referred for endocrine review for a past
diagnosis of “Turner’s syndrome”. She was born to
consanguineous parents and reportedly had abnormal geni-
talia at birth. Growth and development were unremarkable
until the teenage years when spontaneous puberty did not
occur. At age 25, she came to medical attention after frac-
turing her right radius following a fall onto her outstretched
hand. Bone densitometry revealed osteoporosis (T-score
spine -2.5, total hip -1.7). Oestradiol 1 mg per day, Alendro-
nate and Calcium carbonate with Vitamin D2 were com-
menced. Abnormal genitalia were again noted. She was
referred to a surgical centre in India, where an examination
under anaesthesia and laparoscopy revealed clitoromegaly,
partial fusion of urethra and vagina (Prader classification 3),
hypoplastic uterus and bilateral streak ovaries which were
excised (Figure 1) [25]. Histological examination of thepoplastic uterus and adnexae, including bilateral streak ovaries are shown.
Table 1 Biochemical evaluation of the patient
Test Patient Reference range
Follicle stimulating hormone 32 <12 mIU/L**
Luteinizing hormone 17 <12 mIU/L**
Testosterone 0.89 <2 nmol/L
Progesterone <2 <6 nmol/L*
Sex-hormone binding globulin 45 25-90 nmol/L
Dehydroepiandrosterone sulphate 5.2 1-8.5 μmol/L
17-hydroxyprogesterone 2.4 0.2-11.3 nmol/L
Anti-mullerian hormone <3 pmol/L (below 25th
percentile for age)
Thyroid-stimulating hormone 2.2 0.5-4 mIU/L
Free thyroxine 15 10-25 pmol/L
Oral glucose tolerance
test - fasting glucose
6.1 <5.2 mmol/L
Oral glucose tolerance
test – 2 hour glucose
7.5 <7.8 mmol/L
Glycosylated haemoglobin 6.7, 7.1 <5.5%
Fasting insulin 57 <12 mU/L
Total cholesterol 5.9 <5.5 mmol/L
HDL-cholesterol 1.4 1.0-2.2 mmol/L
LDL-cholesterol 3.6 <3.7 mmol/L
Triglycerides 2 0.3-2 mmol/L




Alkaline phosphatase (ALP) 134 30-100 U/L
Alanine aminotransferase (ALT) 41 <55 U/L
Aspartate aminotransferase (AST) 38 <45 U/L
*Hormone measurements were made whilst the patient was on
oestrogen replacement.
**Reference range quoted is for the follicular phase of the menstrual cycle.
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no evidence of ovulation.
On referral to us after migration to Australia, the pa-
tient, aged 32, reported good health other than recurrent
perineal infections which had been treated with antibi-
otics and drainage via abscess incision on several occa-
sions. Surgical reconstruction of the urogenital sinus is
planned. Her height was 180 cm, she had predominant
abdominal obesity (waist circumference 131 cm, hip cir-
cumference 115 cm) and eunuchoidal proportions (arm
span 191 cm, lower segment 103 cm). Her height was
well above her mid-parental predicted height of 161 cm
(father 170 cm, mother 165 cm). Her only sibling, a
younger brother, has a height of 193 cm at age 30, but
was unavailable for detailed examination. She did not
have a webbed neck, goitre or high arched palate. Her
blood pressure was in the upper normal - borderline
hypertensive range at 130–145/80–100 mmHg. She was
not hirsute; breasts, pubic and axillary hair were normal
(Tanner stage 5). Appearance of the external genitalia
has been described. Her general examination was other-
wise within normal limits. The results of hormonal
evaluation (on oestrogen) are shown in Table 1. Bio-
chemical testing revealed impaired fasting glucose, dysli-
pidaemia and insulin resistance (Table 1). Repeat
densitometry revealed osteopenia (T-score spine -2.1,
T-score total hip -1.0). Moderate hepatic steatosis was
evident on abdominal ultrasound.
The karyotype obtained on both peripheral blood lym-
phocytes and cultured fibroblasts (n = 134) was 46, XX.
Based on the clinical history, we suspected aromatase
deficiency and Sanger sequenced the nine coding exons
of CYP19A1. We also sequenced the coding exons of
P450-oxidoreductase (POR), the electron donor for cyto-
chrome P450 enzymes (including CYP19A1), which has
been associated with a phenotype of ambiguous genitalia
and, via consequent dysfunction of CYP19A1, could
result in maternal virilisation in pregnancy [26]. Prior
written, informed consent was obtained from the pa-
tient. Primers and sequencing methods are presented in
Additional file 1 (Methods).
Sequencing of POR revealed two synonymous single
nucleotide polymorphisms (rs1057870 and rs2228104),
unrelated to the patient’s phenotype. The patient had
a novel 27-base pair duplication in exon 8 of CYP19A1
(p.Ala306_Ser314dup) (Figure 2a, 2b; full genomic refer-
ence presented in Additional file 1 (Results)). Whilst she
is most likely to be homozygous for the observed muta-
tion, her parents were unavailable for testing and hence
we are unable to exclude hemizygosity. The CYP19A1
mutation would be expected to result in a duplication of
nine amino acids (p.Ala306_Ser314dup) in the protein.
This duplication occurs within the aromatase α-helix, a
region crucial for binding of the cofactor protoporphyrinIX and the substrate androstenedione [7,27]. The inser-
tion of this long sequence (approximately one third of
the α-helix; Figure 2c, 2d and Additional file 2) would
induce a major disruption of the α-helix conformation.
Prediction tools of protein secondary structure consist-
ently suggest a break of the α-helix around the middle,
turning a continuous helix into the structure of helix-
coil-helix [28-30]. This would be likely to disrupt
substrate and cofactor binding resulting in a lack of
oestrogen synthesis (Figure 2c).
Most individuals reported with CYP19A1 deficiency
have been homozygous for loss-of-function mutations
and born to consanguineous parents [8-13]. Up until re-
cently, all reported mutations have been in coding exons,
mostly in exons 9 and 10, which encode the substrate
(androgen) binding site and haem-binding domains,
respectively [9]. Recently, a patient with aromatase defi-
ciency was found to be heterozygous for a novel muta-
tion (p.Asn411Ser) in exon 9 [10]. In vitro studies
Figure 2 A novel duplication of 27 base pairs in the CYP19A1 gene, was identified in the patient reported here. This duplication is
predicted to disrupt a critical α-helix of the aromatase enzyme. a. A schematic diagram of the aromatase gene, comprised of nine coding exons
(exons 2-9). The location of the novel duplication identified in our patient in exon 8 is shown. b. Results of Sanger sequencing showing a 27 base
pair duplication in exon 8 of the CYP19A1 gene from the patient (chr15 (hg19): g.51507347_51507373dup, NM_031226.2: c.915_941dup; NP_112503.1:
p.Ala306_Ser314dup) (visualised in Mutation Surveyor® software (Version 2.51, SoftGenetics LLC, Philadelphia, USA)). c. Crystallographic structure of
human wild-type aromatase in complex with the cofactor protoporphyrin IX and the substrate androstenedione. The segment of an α-helix in green
shows where the duplication occurs. N- and C-terminuses of the α-helix are in orange and magenta, respectively. The rest of aromatase is shown in
blue. Protoporphyrin IX, white, and androstenedione, grey. The crystallographic structure is from reference 1 and visualised in PyMOL (Version 1.5.0.3,
Schrödinger, LLC). A three-dimensional image of this is provided in the accompanying Additional file 2. d. A close-up showing the α-helix providing
binding sites of protoporphyrin IX (white) and androstenedione (grey).
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co-expressed with the wildtype, the enzyme activity of
the mutant was approximately 65% of wildtype; compat-
ible with a recessive disease and thus the mutation alone
did not explain the phenotype. There was a heterozy-
gous, paternally inherited C > T variant -41 base pairs
upstream of exon 1, in placental promoter I.1, a previ-
ously observed polymorphism (rs6493497) [10,31]. In
vitro studies revealed a 50% reduction in transactivation
ability of the placental promoter harbouring the muta-
tion, compared with wildtype [10].
Our patient had several clinical features in common with
the first female patient recently described with oestrogen
resistance due to a novel homozygous missense mutation
in a highly conserved region of exon 5 of the oestrogen
receptor α (ESR1) [32]. Both lacked spontaneous breast
development, and had primary amenorrhoea and osteopae-
nia. The patient with oestrogen resistance had delayed
bone age and unfused epiphyses; in our patient whilst
x-rays were not available we surmise from her eunuchoidal
proportions that epiphyseal fusion of long bones was de-
layed [32]. The phenotype of tall stature, continuing linear
growth into adulthood, delayed bone age, osteoporosis and
eunuchoidal skeletal proportions is also well described in
adult aromatase deficient males [33]. That it corrects with
oestrogen treatment in both genders, reflects the common
role across genders of oestrogen in bone development [34].
Our patient had a phenotype of metabolic syndrome
not present in the patient with oestrogen resistance [32].
The absence of the metabolic phenotype in the latter
case is in contrast with the only previously reported pa-
tient with an ESR1 mutation [35,36]. In aromatase defi-
cient females, the relationship between insulin resistance
and oestrogen deficiency is unclear. A 14 year old female
had normalisation of mild dyslipidaemia with oestrogen
treatment [13]. However, a nine year old female had se-
vere insulin resistance despite treatment with oestrogen
and metformin [23]. It was postulated that in utero ex-
posure to high levels of androgens or lack of oestrogens
altered foetal programming of insulin sensitivity. Aroma-
tase deficient adult men have a variable phenotype of
metabolic syndrome, which improves with oestrogen
treatment [14,34,37-39]. The development of central
obesity post-menopausally is also considered a result of
oestrogen deficiency.
The phenotype of the CYP19A1 knockout (ArKO)
mouse suggests an association between aromatase defi-
ciency and metabolic perturbations [40,41]. Aging ArKO
mice had progressively greater accumulation of visceral
adiposity than wild-type, which regressed after adminis-
tration of oestrogen [42]. Elevated cholesterol, insulin
levels and glucose intolerance and hepatic steatosis have
also been noted [42,43]. Oestrogen treatment improved
glucose tolerance and reversed hepatic steatosis in maleArKO mice [43,44]. Thus, the majority of the available
data infer that prolonged oestrogen deficiency is associ-
ated with a metabolic syndrome. However, there may be
a gender difference in the mechanisms. High androgen
levels have been associated with peripheral insulin resist-
ance in women, but not in men [45,46]. This may be
due to differences in the androgen-oestrogen ratio and
its effects on cellular metabolism.
The patient we report exhibited evidence of in utero
androgenisation of genitalia [47]. Subsequent failure of
pubertal development, untreated during the adolescent
years, ensued and she eventually came to medical atten-
tion with a minimal trauma fracture at age 25, prompt-
ing oestrogen replacement. She did not have features of
progressive virilisation. This may reflect relatively early
loss of ovarian function as a source of androgens. She
had eunuchoidal proportions, a result of continued lin-
ear growth in adulthood due to unfused epiphyses in the
absence of oestrogen. Genetic analyses revealed a novel
27 base duplication in exon 8 of CYP19A1, likely to
result in a complete loss of function of the aromatase
enzyme, the key enzyme regulating the oestradiol:testos-
terone ratios in tissues. A limitation of this work is that
we have not performed functional studies to verify the
effect of the duplication on protein function; however
the clinical presentation and the correlation with cases
already reported and with the ArKO mouse model is
compelling for this being a loss of function mutation.
Unexpectedly, our patient had had streak ovaries ex-
cised. We caution that the histological slides were un-
available for verification and streak ovaries have not
been described in association with aromatase deficiency.
Polycystic ovaries and regression of ovarian cysts have
been described previously in cases of aromatase defi-
ciency [14-18,48]. Other cases had normal ovarian
morphology, even in the absence of prior oestrogen
treatment [10,11]. Thus, there is no consistent ovarian
phenotype in aromatase deficiency and, furthermore,
the phenotype may be modulated by treatment. In our
patient, the ovarian morphology may be a result of
oestrogen treatment.
Alternatively, extrapolating from observations in the
ArKO mouse, we speculate that the streak ovaries may
be an inherent manifestation of CYP19A1 deficiency
[40,41]. Follicular development in ArKO is abnormal in
an age dependent manner, with an early block in follicu-
lar development at the antral stage with absent corpora
lutea, then haemorrhagic cysts and later, absent second-
ary and antral follicles and atresia of primary follicles
with increased collagen deposition [40,41]. The longer
life span of the human may permit more complete fol-
licular atresia and collagen deposition mimicking the
classical streak ovaries seen in Turner’s syndrome. Streak
ovaries may not have been previously described in
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visualization of the ovaries and some of the cases may
have been too young to develop this manifestation. In
addition, some of the cases may have had CYP19A1 mu-
tations that allowed some residual aromatase function
with a less severe ovarian atretic phenotype.
Another possibility is that our patient may have an-
other cause of the streak ovaries such as XO mosaicism
localised to the ovaries, although the normal XX karyo-
type makes this less likely. Streak ovaries are not clearly
associated with any other disorder but Turner’s syn-
drome. In view of the small numbers of CYP19A1 defi-
ciency cases reported, this manifestation should be
noted particularly since this finding may be relevant to
ovarian developmental biology.
Conclusions
We report a case of the very rare condition, aromatase
deficiency, due to a novel aromatase mutation and cor-
responding enzyme region distinct from previous re-
ports. Our case is unique because it is the first reported
case of aromatase deficiency in a female not treated until
adulthood, and it depicts, for the first time, the natural
history of aromatase deficiency in females. This comprises
a phenotype of osteopaenia, tall stature and metabolic syn-
drome, as occurs in aromatase deficient males in whom,
similarly to our patient, diagnosis and treatment are de-
layed. Streak ovaries may represent an extension of the
clinical spectrum of this disorder and appears to correlate
with findings in the aromatase knockout mouse model.
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